Latest Event
January 25, 2023
PPMD Webinar
Latest Financial Results

Q3 2023
Quarter Ended Sep 30, 2023
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2022
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.

Company Overview
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s current focus is on developing exosomes capable of delivering nucleic acids as well as proteins to treat or prevent a variety of diseases.
IR Contacts
Corporate & Research Headquarters
Capricor Therapeutics, Inc.
10865 Road to the Cure
Suite 150
San Diego, CA 92121
United States
T: 858-727-1755
Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
United States
https://www.astfinancial.com
Investor Relations
LifeSci Advisors, LLC
Joyce Allaire
T: 617-435-6602
jallaire@lifesciadvisors.com